Calzada Limited (CALZF) 0.1000 $CALZF Cartilage

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Calzada Limited (CALZF) 0.1000 $CALZF

Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Bone Degeneration Market Report 2013
M2 - Mon Dec 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/94cktb/bone_degeneration) has announced the addition of the "Global Bone Degeneration Market Report 2013" report to their offering. This report provides information on the therapeutic development for Bone Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Degeneration. The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bone Degeneration. - A review of the Bone Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Table of Contents List of Tables List of Figures Introduction REPORT COVERAGE Bone Degeneration Overview Therapeutics Development Companies Involved in Bone Degeneration Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Amgen Inc. - Cell Therapeutics, Inc. - Calzada Limited - Alethia Biotherapeutics Inc. - Fate Therapeutics, Inc. - Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/94...generation

Osteoporosis - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Osteoporosis
M2 - Tue Sep 03, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9tgmch/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. Scope - A snapshot of the global therapeutic scenario for Osteoporosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Affectis Pharmaceuticals AG Amgen Inc. B&C Biopharm Biodel Inc. Bone Medical Limited Calzada Limited Critical Pharmaceuticals Limited DONGKOOK Pharmaceutical Co., Ltd. Dongwha Pharm Co., Ltd. Eli Lilly and Company EndoCeutics, Inc. Ensoltek Co., Ltd. F. Hoffmann-La Roche Ltd. Galapagos NV HYUNDAI PHARM. CO., LTD. Hindustan Latex Limited IMMD Inc. Kaken Pharmaceutical Co.,Ltd. Merck & Co., Inc. NeoStem, Inc. Novartis AG Oscotec Inc. Pfizer Inc. Radius Health, Inc. Siena Biotech S.p.A. TSRL, Inc. Uni-Bio Science Group Ltd. Ventria Bioscience Zelos Therapeutics, Inc. Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/9t...teoporosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Bone Disorders - Pipeline Review, H1 2013
M2 - Fri Mar 22, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lqxhlr/bone_disorders) has announced the addition of the "Bone Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Scope - A snapshot of the global therapeutic scenario for Bone Disorders. - A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherap
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Decibel's Bold Move to Trade on OTCQX: A New Era

Updated Category News Views 82

Decibel Sets Sail on the OTCQX Best Market Right off the bat, we're talking about Decibel Cannabis Company Inc. making waves by jumping from the OTCQB to the more reputable OTCQX Best Market. If this doesn’t make you sit up and take notice, I don’t know what will. The ticker OTCQX:DBCCF is now on a stage where it can potentially woo more U.S. investors, and given the...

Continue Reading
Cemig and Huawei's Bold Network Leap: Power Up

Updated Category News Views 120

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Continue Reading
Hebrew Learning Made Simple: Expert's Structured Guide

Updated Category News Views 188

Cracking the Hebrew Code: A Balanced Guide Ever tried staring down a new language script and felt like you were on a sinking ship? That’s where a lot of folks starting off with Hebrew reading find themselves. It's no sunny stroll through a Greek alphabet park—Hebrew's a whole different ballgame. But Diana Yacobi from Sarah & David’s Read Hebrew Now offers a roadmap...

Continue Reading
Duke Energy's Cooling Tips Amid Florida Cold Front

Updated Category News Views 179

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 107

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Data Centers: More Power-Hungry Than Thirsty

Updated Category News Views 147

Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....

Continue Reading
Lavazza 2027 Calendar: Moments of Pleasure Worldwide

Updated Category News Views 248

Capturing Fleeting Joy Through the Lens In 2027, Lavazza sets the stage for an evocative exploration of human pleasure through its iconic calendar. Teaming up with photographers Jim Goldberg, Alex Majoli, and Paolo Pellegrin, the project spans three vibrant cities: New York, Lisbon, and Hong Kong. These masters of the lens invite us to pause and appreciate the understated...

Continue Reading
Immunic, Inc. Steams Ahead: Phase 3 Trials Hinge on MS Data

Updated Category News Views 137

A Pivotal Moment for Immunic We’re staring down a critical December for Immunic, Inc. as they trot out top-line data for their Phase 3 ENSURE trials aimed at relapsing multiple sclerosis (MS). Now, I’m all ears wondering if those trials can hold water — success could morph them from a tinkering biotech into a commercial giant. For market vultures like us,...

Continue Reading
JardogsHealth Taps Industry Titans for Growth Council

Updated Category News Views 181

JardogsHealth: A New Chapter with Strategic Insights You've got to admire when a company rounds up a top-tier brain trust. Such is the case with JardogsHealth, the healthcare AI outfit nestled in Hillsboro, Illinois, as they align their future alongside heavyweights who’ve maneuvered through multiple industries and come out thriving. Their brand-new council includes...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Female Athletes: Herbalife Supports Basketball Combine

Updated Category News Views 324

Herbalife Partners for Women’s College Basketball Stars Herbalife, a leading health and wellness brand, is stepping up to empower female athletes by becoming the Official Nutrition and Hydration Partner for the Lilly 2025 Women's College All-Star Combine. This significant event aims to showcase talented basketball players, allowing them to connect with scouts and...

Continue Reading
FPI Earnings Preview: Traders Eye EPS and Guidance Impact

Updated Category News Views 167

Farmland Partners (NYSE:FPI) is prepped to drop its quarterly earnings on February 18, 2026, and you better believe traders are already sweating over it. Analysts are throwing out estimates pegging the earnings per share (EPS) at $0.19—now, that's not exactly a home run but it's enough to keep eyes glued to the screens as we await the news. The buzz in the air is thick;...

Continue Reading
Celebrate Mom with a Prize from Molly Maid This Mother's Day

Updated Category News Views 138

Celebrate Mother's Day with Molly Maid’s Special Giveaway Mother's Day is a wonderful occasion to honor and pamper the incredible mothers in our lives. This year, Molly Maid® is offering a unique opportunity to celebrate these remarkable women with their annual "Mother's Day Clean Home Giveaway." This giveaway presents a chance for five fortunate winners to each...

Continue Reading
Cure Alzheimer's Fund Welcomes New Research Management Leader

Updated Category News Views 190

Cure Alzheimer's Fund Welcomes New Research Management Leader Cure Alzheimer's Fund is thrilled to announce the appointment of Natasha Hussain, Ph.D., as the new Executive Vice President for Research Management. In her new role, Dr. Hussain is poised to manage and enhance the research opportunities and funding initiatives within the organization. Bringing Expertise to...

Continue Reading
Understanding Disclosure Requirements for Life Science REIT

Updated Category News Views 142

Overview of Disclosure Requirements Understanding the importance of disclosure in the financial world is pivotal for investors. When companies like Life Science REIT Plc are involved, transparency in trading and ownership stakes is crucial. Efforts to remain compliant under various regulations can help build trust among stakeholders and investors alike. Key Entities and...

Continue Reading